Holocene Advisors
HZNP

Holocene Advisors’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Holocene Advisors’s Portfolio HZNP Stock Details HZNP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-279,000
Closed -$30.6M – 1029
2021
Q3 		$30.6M Buy
+279,000
New +$29M 0.17% 166

Other funds holding HZNP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Holocene Advisors's HZNP Position: Q3 2023 in Review

Holocene Advisors sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 20,661 shares — an estimated $2.12M sold.

Holocene Advisors first reported a position in HZNP in Q2 2021 and held it in 5 quarters. The position peaked at $97.6M in Q4 2021. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

  • Holocene Advisors reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
  • Holocene Advisors sold 20,661 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $2.12M.
  • Holocene Advisors first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2021 and held it in 5 quarters.
  • Holocene Advisors's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $97.6M in Q4 2021.
  • 485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Holocene Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.